Completed PHASE4 INTERVENTIONAL 1-arm NCT00554658

Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients

Quetiapine Induced Neuroplasticity in Schizophrenic Patients: A Combined Transcranial Magnetic Stimulation (TMS) and Voxel-based Morphometry (VBM) Study

Sponsor: AstraZeneca

Conditions Schizophrenia

Interventions Quetiapine

Updated 5 times since 2017 Last updated: Oct 21, 2011 Started: Mar 31, 2008 Primary completion: Dec 31, 2010 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Schizophrenia and is currently completed. AstraZeneca leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
University of Regensburg

Data source: University of Regensburg

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Regensburg, Germany